Arena Pharmaceuticals Q4 Earnings Preview

Don't be caught off-guard: Arena Pharmaceuticals ARNA releases its next round of earnings Tuesday.

Want to skip the homework and get all the facts in one place? We thought so. Here is your everything-that-matters guide for today's Q4 earnings announcement after the bell.

Earnings and Revenue

Wall Street analysts see Arena Pharmaceuticals reporting a quarterly loss of 59 cents per share on sales of $7.57 million.

In the same quarter last year, Arena Pharmaceuticals announced EPS of 25 cents on revenue of $85.37 million. Analysts estimate would represent a 336 percent increase in the company's earnings. Revenue would be down 91.13 percent from the same quarter last year.

Here's how the company's reported EPS has stacked up against analyst estimates in the past:

Stock Performance

Over the last 52-week period, shares are up 171.62 percent. Given that these returns are generally positive, long-term shareholders can be satisfied going into this earnings release. Analysts have adjusted their estimates lower for EPS and revenues over the past 90 days. The popular rating by analysts on Arena Pharmaceuticals stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.